Bicara Therapeutics/$BCAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bicara Therapeutics
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Ticker
$BCAX
Sector
Primary listing
Employees
55
Headquarters
Website
BCAX Metrics
BasicAdvanced
$1B
-
-$2.35
-
-
Price and volume
Market cap
$1B
52-week high
$28.09
52-week low
$7.80
Average daily volume
591K
Financial strength
Current ratio
25.796
Quick ratio
25.344
Long term debt to equity
0.267
Total debt to equity
0.514
Profitability
EBITDA (TTM)
-121.003
Effective tax rate (TTM)
-0.30%
Management effectiveness
Return on assets (TTM)
-22.85%
Return on equity (TTM)
-32.71%
Valuation
Price to book
2.34
Price to tangible book (TTM)
2.34
Price to free cash flow (TTM)
-8.076
Free cash flow yield (TTM)
-12.38%
Free cash flow per share (TTM)
-2.313
Growth
Earnings per share change (TTM)
-97.48%
Bulls say / Bears say
In a Phase 1/1b dose expansion for metastatic or advanced cSCC unresponsive to anti–PD-1 therapy, ficerafusp alfa achieved a 30.4% overall response rate and a median 7.0-month progression-free survival, outperforming historical results in this difficult population.
As of March 31, 2025, Bicara had $462.1 million in cash and cash equivalents, supporting operations into the first half of 2029 and reducing immediate financing risk.
Patient enrollment continues in FORTIFI-HN01, the pivotal Phase 2/3 trial of ficerafusp alfa with pembrolizumab in first-line recurrent/metastatic HNSCC, marking progress toward potential approval data.
Ficerafusp alfa is still in Phase 1/1b and pivotal Phase 2/3 trials with no approved products yet, which lengthens the path to commercialization and raises execution risk.
Bicara posted a net loss of $36.8 million in Q1 2025, up from $12.5 million a year ago, showing a high cash burn that could strain reserves before any product reaches approval.
In the Phase 1/1b cSCC group, 74% of patients had dermatitis acneiform and 30% experienced epistaxis, signaling potential side effect concerns that could hinder broader adoption.
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bicara Therapeutics stock?
Bicara Therapeutics (BCAX) has a market cap of $1B as of October 17, 2025.
What is the P/E ratio for Bicara Therapeutics stock?
The price to earnings (P/E) ratio for Bicara Therapeutics (BCAX) stock is 0 as of October 17, 2025.
Does Bicara Therapeutics stock pay dividends?
No, Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders as of October 17, 2025.
When is the next Bicara Therapeutics dividend payment date?
Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Bicara Therapeutics?
Bicara Therapeutics (BCAX) does not currently have a Beta indicator.